Bile acid reduces liver fat in mice through two pathways

Chiba University researchers have identified two biological pathways through which hyodeoxycholic acid reduces liver fat in mice, offering new insights into MASLD.

Researchers at Chiba University have found that hyodeoxycholic acid (HDCA), a bile acid, can reduce liver fat in mice through two distinct biological pathways, identifying potential targets for future metabolic dysfunction-associated steatotic liver disease (MASLD) research.

The study, published in Cell Reports, found that HDCA activates peroxisome proliferator-activated receptor alpha (PPARα), a protein involved in regulating fatty-acid breakdown. The researchers identified two mechanisms through which the bile acid increases PPARα activity: one involving immune cells and another involving the gut hormone glucagon-like peptide-1 (GLP-1).

MASLD, previously known as non-alcoholic fatty liver disease (NAFLD), affects approximately one-quarter of adults worldwide. The condition involves excess fat accumulation in the liver and can progress to inflammation, liver damage and fibrosis.

Understanding the mechanisms responsible for hepatic steatosis, the accumulation of fat in liver cells, could help researchers identify new approaches to managing the condition.

HDCA reduces liver fat without affecting body weight

The research team, led by Professor Takashi Miki of Chiba University’s Graduate School of Medicine, investigated HDCA in mice fed a high-fat diet.

At a 0.25% dose, HDCA reduced blood glucose levels and liver triglyceride accumulation while improving liver function. These effects occurred without changes in body weight, suggesting that the reduction in liver fat was not simply a consequence of weight loss.

The researchers then investigated PPARα, which regulates genes involved in fatty-acid metabolism.

HDCA increased PPARα activity, but when the researchers tested mice lacking the protein, the treatment no longer prevented hepatic fat accumulation. This indicated that PPARα was necessary for the observed effects.

Two pathways activate PPARα

The team identified two distinct pathways through which HDCA influenced PPARα activity.

The first involved invariant natural killer T (iNKT) cells, a type of immune cell found in the liver. HDCA increased the number of these cells and stimulated the production of interferon-gamma (IFN-γ), a signalling molecule that activated PPARα in liver cells.

This activation increased the expression of genes involved in fatty-acid breakdown, helping reduce fat accumulation.

The second pathway involved GLP-1, a gut hormone that regulates metabolism.

HDCA increased GLP-1 levels, and experiments using mice without the GLP-1 receptor showed that this signalling pathway was necessary for the reduction in liver fat.

To investigate the relationship between GLP-1 and the immune pathway, the researchers also tested liraglutide, a GLP-1 receptor agonist used to treat type 2 diabetes.

Liraglutide reduced liver fat in normal mice and those lacking iNKT cells, but not in mice lacking PPARα. The findings indicated that GLP-1 can reduce liver fat through PPARα without requiring iNKT cells.

Findings identify potential therapeutic targets

Together, the results suggest that HDCA influences liver fat accumulation through two separate pathways that converge on PPARα.

“Both HDCA and the GLP-1 receptor agonist liraglutide exhibited potent anti-steatotic effects in mice in a PPARα-dependent manner,” said Miki.

The findings highlight PPARα as a potential target for further investigation into treatments for hepatic steatosis.

However, the research remains preclinical. Further studies will be needed to establish whether HDCA has similar effects in humans and whether it could eventually contribute to the development of MASLD therapies.

Mail Icon

news via inbox

Sign up for our newsletter and get the latest news right in your inbox